CD274 and neoplasm: ORR: 28.4 or 23.8% in PD-L1+ patients using ≥5% or ≥1% PD-L1+ cutoff (prevalence: 31 and 46%, respectively); 16.1% in PD-L1− patients; tumor-membrane PD-L1 expression was evaluated by the Dako PD-L1 IHC 28-8 pharmDx kit